Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
LCDD
MCID: LGH004
MIFTS: 47

Light Chain Deposition Disease (LCDD)

Categories: Blood diseases, Immune diseases, Nephrological diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Light Chain Deposition Disease

About this section

MalaCards integrated aliases for Light Chain Deposition Disease:

Name: Light Chain Deposition Disease 53 59
Light-Chain Deposition Disease 53
Light Chain Disease 73
Lcdd 59

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Nephrological diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare renal diseases
Rare haematological diseases


External Ids:

Orphanet 59 ORPHA93558
UMLS via Orphanet 74 C0238239
ICD10 via Orphanet 34 D89.8
UMLS 73 C0238239
Sources

Summaries for Light Chain Deposition Disease

About this section
NIH Rare Diseases : 53 Light chain deposition disease (LCDD) is a rare condition characterized by the deposition of specific proteins (monoclonal light chains) in the kidneys and other organs. Light chains are used to make antibodies that the body needs to fight infection. People with LCDD make too many light chains, which get deposited in many body tissues. While LCDD can occur in any organ, the kidneys are always involved. Signs and symptoms of LCDD may include protein in the urine; decreased kidney function; and/or nephrotic syndrome. Rarely, a person with LCDD may have symptoms from cardiac (heart) or liver involvement. The underlying cause of LCDD is unknown. It is often associated with multiple myeloma. LCDD may progress to multiple myeloma, or it may be present with multiple myeloma when it is first diagnosed. The goal of treating LCDD is to slow the production of light chains and their damage to organs. Treatment may include chemotherapy with a drug called Bortezomib; autologous stem cell transplantation; immunomodulatory drugs; and/or kidney transplant. If untreated, end-stage renal disease occurs in 70% of cases.

MalaCards based summary : Light Chain Deposition Disease, also known as light-chain deposition disease, is related to lacrimal duct defect and amyloidosis. An important gene associated with Light Chain Deposition Disease is ACTC1 (Actin, Alpha, Cardiac Muscle 1), and among its related pathways/superpathways are Integrin Pathway and Degradation of the extracellular matrix. The drugs Bortezomib and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and heart, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 76 Light chain deposition disease (LCDD) is a rare blood cell disease which is characterized by deposition... more...

Sources

Related Diseases for Light Chain Deposition Disease

About this section

Diseases related to Light Chain Deposition Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
# Related Disease Score Top Affiliating Genes
1 lacrimal duct defect 11.8
2 amyloidosis 10.5
3 myeloma, multiple 10.4
4 lymphoma 10.2
5 fibromatosis, gingival, 1 10.2 MMP1 MMP2
6 multicentric osteolysis, nodulosis, and arthropathy 10.2 MMP14 MMP2
7 winchester syndrome 10.2 MMP14 MMP2
8 conjunctivochalasis 10.1 MMP1 MMP2
9 mid-dermal elastolysis 10.1 MMP12 MMP7
10 chronic actinic dermatitis 10.1 MMP1 MMP9
11 chromoblastomycosis 10.1 MMP1 MMP9
12 extracranial arteriovenous malformation 10.1 MMP2 MMP9
13 villous adenocarcinoma 10.1 MMP2 MMP9
14 al amyloidosis 10.1
15 septic arthritis 10.1 MMP1 MMP2
16 lentigo maligna melanoma 10.1 MMP2 MMP9
17 psammomatous meningioma 10.1 MMP2 MMP9
18 acute transverse myelitis 10.1 MMP2 MMP9
19 transverse myelitis 10.1 MMP2 MMP9
20 ischemic colitis 10.1 MMP2 MMP9
21 conjunctival nevus 10.1 MMP2 MMP9
22 parotitis 10.1 MMP2 MMP9
23 collagenous colitis 10.1 MMP1 MMP9
24 brain glioblastoma multiforme 10.1 MMP7 MMP9
25 corneal ulcer 10.1 MMP2 MMP9
26 pediatric multiple sclerosis 10.1 MMP7 MMP9
27 nasal cavity squamous cell carcinoma 10.1 MMP2 MMP9
28 immunotactoid glomerulopathy 10.1
29 coronary artery aneurysm 10.0 MMP1 MMP12 MMP7
30 keloids 10.0 MMP1 TNC
31 lymphangioleiomyomatosis 10.0 MMP1 MMP14 MMP2
32 chronic venous insufficiency 10.0 MMP1 MMP9
33 malignant giant cell tumor of soft parts 10.0 ACTC1 CD68
34 venous insufficiency 10.0 MMP1 MMP9
35 lymph node disease 10.0 MMP1 MMP14
36 pulmonary emphysema 10.0 MMP1 MMP12 MMP9
37 infantile liver failure syndrome 1 10.0
38 portal hypertension 10.0
39 nephrotic syndrome 10.0
40 restrictive cardiomyopathy 10.0
41 light and heavy chain deposition disease 10.0
42 heavy chain deposition disease 10.0
43 sialadenitis 10.0 MMP2 TNC
44 ischemic fasciitis 10.0 ACTC1 CD68
45 gliosarcoma 10.0 ACTC1 MMP2 MMP9
46 pelvic organ prolapse 10.0 MMP1 MMP9
47 cryptogenic organizing pneumonia 10.0 MMP9 TNC
48 odontogenic myxoma 10.0 MMP1 MMP2 MMP9
49 hypertensive heart disease 10.0 MMP1 MMP2 MMP9
50 aortic aneurysm, familial thoracic 1 10.0 MMP1 MMP2 MMP9

Graphical network of the top 20 diseases related to Light Chain Deposition Disease:



Diseases related to Light Chain Deposition Disease
Sources

Symptoms & Phenotypes for Light Chain Deposition Disease

About this section

MGI Mouse Phenotypes related to Light Chain Deposition Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.56 ACTC1 MMP1 MMP12 MMP14 MMP2 MMP7
2 immune system MP:0005387 9.17 CD68 MMP1 MMP12 MMP14 MMP2 MMP7
Sources

Drugs & Therapeutics for Light Chain Deposition Disease

About this section

Drugs for Light Chain Deposition Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
2
Melphalan Approved Phase 3,Phase 2,Not Applicable 148-82-3 4053 460612
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
6
Lenalidomide Approved Phase 3 191732-72-6 216326
7
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
8
Daratumumab Approved Phase 3 945721-28-8
9 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
10 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
11 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
12 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
13 Antiemetics Phase 3,Phase 2,Phase 1,Not Applicable
14 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
15 Alkylating Agents Phase 3,Phase 2
16 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
17 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
18 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
19 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
20
protease inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
21 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
22 BB 1101 Phase 3,Phase 2,Phase 1,Not Applicable
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
24 phenylalanine Phase 3,Phase 2
25 Antineoplastic Agents, Alkylating Phase 3,Phase 2
26 Autonomic Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Anti-Infective Agents Phase 3,Phase 2,Phase 1
28 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
29 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
30 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
31 Antibodies, Monoclonal Phase 3
32 Antibodies Phase 3,Phase 2,Not Applicable
33 Immunoglobulins Phase 3,Phase 2,Not Applicable
34
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
35
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
36
Cyclophosphamide Approved, Investigational Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
37
Etoposide Approved Phase 2 33419-42-0 36462
38
Lenograstim Approved, Investigational Phase 2 135968-09-1
39
Doxil Approved June 1999 Phase 2 31703
40 Interferon-alpha Phase 2
41 interferons Phase 2
42 Antiviral Agents Phase 2
43 Dexamethasone 21-phosphate Phase 2
44 Antibiotics, Antitubercular Phase 2
45 Antineoplastic Agents, Phytogenic Phase 2
46 Etoposide phosphate Phase 2
47 Antirheumatic Agents Phase 2
48 Topoisomerase Inhibitors Phase 2
49 Myeloma Proteins Phase 2,Not Applicable
50 Paraproteins Phase 2,Not Applicable

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Completed NCT01078454 Phase 3 melphalan;dexamethasone;bortezomib
2 Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Completed NCT01109004 Phase 3 Lenalidomide;lenalidomide, bortezomib and dexamethasone;Lenalidomide
3 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Active, not recruiting NCT01169337 Phase 3 Lenalidomide
4 A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma Active, not recruiting NCT02195479 Phase 3 Velcade;Melphalan;Prednisone;Daratumumab;Dexamethasone
5 S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis Completed NCT00002849 Phase 2 dexamethasone
6 Bortezomib With Melphalan and Prednisone for Multiple Myeloma Completed NCT00734149 Phase 2 Bortezomib;Melphalan;Prednisone
7 Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease Active, not recruiting NCT00520767 Phase 2 bortezomib;dexamethasone;melphalan
8 Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma Active, not recruiting NCT01849783 Phase 2 dexamethasone;cisplatin;doxorubicin;cyclophosphamide;etoposide;bortezomib;thalidomide;melphalan
9 HD Melphalan and SCT in Patients With IGDD or LCDD Terminated NCT00681044 Phase 2 melphalan
10 Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed NCT01533194 Phase 1
11 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
12 First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD Suspended NCT01728259 Phase 1 pomalidomide;bortezomib;dexamethasone
13 Registry for Adults With Plasma Cell Disorders (PCD's) Recruiting NCT03717844
14 Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis Active, not recruiting NCT01383759 Not Applicable Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
15 Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects Terminated NCT01018927

Search NIH Clinical Center for Light Chain Deposition Disease

Sources

Genetic Tests for Light Chain Deposition Disease

About this section
Sources

Anatomical Context for Light Chain Deposition Disease

About this section

MalaCards organs/tissues related to Light Chain Deposition Disease:

41
Kidney, Liver, Heart, B Cells, Skin, Brain, Bone
Sources

Publications for Light Chain Deposition Disease

About this section

Articles related to Light Chain Deposition Disease:

(show top 50) (show all 184)
# Title Authors Year
1
Light Chain Deposition Disease with Bullous Skin Lesions Mimicking Atypical Bullous Pemphigoid. ( 29135016 )
2018
2
Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report andA review of the literaturea8c. ( 29393843 )
2018
3
Light Chain Deposition Disease Associated With Multiple Myeloma Developing in Late Pregnancy. ( 29507277 )
2018
4
Acquired Fanconi syndrome secondary to light chain deposition disease associated with monoclonal gammopathy of renal significance: A case report. ( 30200082 )
2018
5
Unmasking and successful management of light chain deposition disease of kidney in pregnancy: a complex case, mirroring the complex needs of pregnancy with kidney disease in India. ( 30187379 )
2018
6
Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease: A Case Series. ( 30101913 )
2018
7
Primary idiopathic CNS non-amyloidogenic light chain deposition disease complicated by treatment-resistant focal seizure disorder. ( 30424969 )
2018
8
Detection and Treatment of Monoclonal Gammopathy of Renal Significance With Progression to Light Chain Deposition Disease. ( 28809601 )
2017
9
Primary CNS Nonamyloidogenic Light Chain Deposition Disease: Case Report and Brief Review. ( 28669250 )
2017
10
Primary Central Nervous System Lymphoma With Light Chain Deposition Disease (Aggregoma). ( 29280764 )
2017
11
Light Chain Deposition Disease Diagnosed with Laser Micro-dissection, Liquid Chromatography, and Tandem Mass Spectrometry of Nodular Glomerular Lesions. ( 28050001 )
2017
12
Cardiac light-chain deposition disease relapsing in the transplanted heart. ( 28562083 )
2017
13
Cutaneous Light Chain Deposition Disease: A Report of 2 Cases and Review of the Literature. ( 28953013 )
2017
14
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. ( 28383130 )
2017
15
Treatment of idiopathic light chain deposition disease: complete remission with bortezomib and dexamethasone. ( 28001187 )
2016
16
Surgical Management of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Associated With Light-Chain Deposition Disease. ( 27211983 )
2016
17
Spontaneous splenic rupture in a patient with light-chain deposition disease undergoing autologous peripheral blood stem cell transplantation. ( 27384856 )
2016
18
A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma. ( 26988342 )
2016
19
Five Sequential Evaluations of Renal Histology in a Patient with Light Chain Deposition Disease. ( 27746438 )
2016
20
Nodular pulmonary light chain deposition disease. ( 27306574 )
2016
21
Clinicopathological characteristics and outcomes of light chain deposition disease: an analysis of 48 patients in a single Chinese center. ( 27056200 )
2016
22
Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach. ( 27101986 )
2016
23
Animal Models of Light Chain Deposition Disease Provide a Better Understanding of Nodular Glomerulosclerosis. ( 26794829 )
2016
24
Intracystic hemorrhage in a patient with pulmonary cystic disorder related to light-chain deposition disease. ( 27756655 )
2016
25
Light Chain Deposition Disease After Kidney Transplantation With Long Graft Survival: Case Report. ( 26915878 )
2016
26
ATYPICAL MACULOPATHY IN A PATIENT WITH LIGHT CHAIN DEPOSITION DISEASE MIMICKING ADVANCED GEOGRAPHIC ATROPHY. ( 26934302 )
2016
27
Unusual case of light chain deposition disease kappa restricted in a case of multiple myeloma. ( 27728483 )
2016
28
Nodular pulmonary light chain deposition disease: an entity associated with SjAPgren syndrome or marginal zone lymphoma. ( 26502747 )
2016
29
Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male. ( 28083151 )
2016
30
Light Chain Deposition Disease in an Older Adult Patient Successfully Treated with Long-term Administration of Bortezomib, Melphalan and Prednisone. ( 27181540 )
2016
31
OCULAR MANIFESTATIONS OF MONOCLONAL IMMUNOGLOBULIN LIGHT CHAIN DEPOSITION DISEASE. ( 27315323 )
2016
32
Bortezomib Based Chemotherapy for Light Chain Deposition Disease. ( 27762125 )
2016
33
Unusual Presentation of Light Chain Deposition Disease: A Case Report. ( 27437235 )
2016
34
ENHANCED DEPTH IMAGING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FEATURES OF LIGHT CHAIN DEPOSITION DISEASE. ( 26398301 )
2015
35
Natural history and outcome of light chain deposition disease. ( 26392598 )
2015
36
Light-Chain Deposition Disease Successfully Treated with Bortezomib in an Elderly Patient: A Case Report and Review of the Literature. ( 26568005 )
2015
37
AJKD Atlas of Renal Pathology: Light Chain Deposition Disease. ( 26593321 )
2015
38
Clinical and Prognostic Differences among Patients with Light Chain Deposition Disease, Myeloma Cast Nephropathy and Both. ( 25860232 )
2015
39
Pulmonary light-chain deposition disease: CT and pathology findings in nine patients. ( 25659938 )
2015
40
Enlightening light chain deposition disease. ( 26705338 )
2015
41
Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge. ( 25441103 )
2015
42
Blood stem cell transplantation to treat cystic lung light chain deposition disease. ( 26160867 )
2015
43
Nonamyloid tumoral light-chain-deposition disease (aggregoma) of the paraspinal region. ( 26253133 )
2015
44
Education and imaging. Hepatobiliary and Pancreatic: Portal hypertension due to hepatic light chain deposition disease. ( 24832781 )
2014
45
Osteolytic femoral lesion detected by sonography in a case of light chain deposition disease. ( 24449208 )
2014
46
Isolated intracerebral light chain deposition disease: novel imaging and pathologic findings. ( 25084689 )
2014
47
Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist. ( 24619059 )
2014
48
Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case report. ( 25249814 )
2014
49
Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach? ( 25022598 )
2014
50
Hypertension, renal failure, and edema in a 38-year-old man: light chain deposition disease; a case report and review of the literature. ( 24772399 )
2014
Sources

Variations for Light Chain Deposition Disease

About this section
Sources

Expression for Light Chain Deposition Disease

About this section
Search GEO for disease gene expression data for Light Chain Deposition Disease.
Sources

Pathways for Light Chain Deposition Disease

About this section

Pathways related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Integrin Pathway 64
Show member pathways
 13.15 MMP1 MMP12 MMP2 MMP7 MMP9 TNC
2
Degradation of the extracellular matrix 66
Show member pathways
 12.46 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
3
G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins 22
Show member pathways
 11.98 MMP1 MMP12 MMP2 MMP7 MMP9 TNC
4
TGF-beta Signaling Pathway (WikiPathways) 1
11.87 MMP1 MMP12 TNC
5
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 11.86 MMP2 MMP7 MMP9 TNC
6
Colorectal Cancer Metastasis 64
11.85 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
7
Adhesion 4
11.82 MMP14 MMP2 MMP9
8
Interleukin-4 and 13 signaling 66
11.78 MMP1 MMP2 MMP9
9
Angiogenesis (CST) 4
11.62 MMP2 MMP7 MMP9 TNC
10
Bladder cancer 37 1
11.56 MMP1 MMP2 MMP9
11
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.49 MMP1 MMP2 MMP9
12
AGE/RAGE pathway 1
11.44 MMP14 MMP2 MMP7 MMP9
13
Matrix Metalloproteinases 1
Show member pathways
 11.43 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
14
amb2 Integrin signaling 1
11.3 MMP2 MMP9
15
Osteopontin-mediated events 1
Show member pathways
 11.26 MMP2 MMP9
16
Cell adhesion_Cell-matrix glycoconjugates 22
11.26 MMP1 MMP9 TNC
17
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.18 MMP1 MMP2 MMP9
18
A-beta Pathways: Uptake and Degradation 65
11.11 MMP2 MMP9
19
Syndecan-4-mediated signaling events 1
11.09 MMP9 TNC
20
Plasma membrane estrogen receptor signaling 1
11.01 MMP2 MMP9
21
A-beta Pathways: Plaque Formation and APP Metabolism 65
10.95 MMP2 MMP9
22
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
10.9 MMP1 MMP2
23
Cell adhesion_ECM remodeling 22
10.89 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
24
Syndecan-1-mediated signaling events 1
10.84 MMP1 MMP7 MMP9
Sources

GO Terms for Light Chain Deposition Disease

About this section

Cellular components related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 IGKC IGKV1-5 MMP1 MMP12 MMP2 MMP7
2 extracellular space GO:0005615 9.61 ACTC1 IGKC IGKV1-5 MMP12 MMP14 MMP2
3 blood microparticle GO:0072562 9.43 ACTC1 IGKC IGKV1-5
4 extracellular matrix GO:0031012 9.17 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9

Biological processes related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.76 IGKC IGKV1-5 MMP1 MMP12 MMP14 MMP2
2 leukocyte migration GO:0050900 9.62 IGKC IGKV1-5 MMP1 MMP9
3 cellular protein metabolic process GO:0044267 9.58 MMP1 MMP2 TNC
4 response to hypoxia GO:0001666 9.54 MMP12 MMP14 MMP2
5 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.46 MMP2 MMP9
6 embryo implantation GO:0007566 9.43 MMP2 MMP9
7 endodermal cell differentiation GO:0035987 9.43 MMP14 MMP2 MMP9
8 extracellular matrix disassembly GO:0022617 9.43 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
9 collagen catabolic process GO:0030574 9.1 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9

Molecular functions related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.88 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
2 zinc ion binding GO:0008270 9.85 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
3 peptidase activity GO:0008233 9.73 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
4 metallopeptidase activity GO:0008237 9.63 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
5 endopeptidase activity GO:0004175 9.62 MMP1 MMP12 MMP14 MMP9
6 metalloendopeptidase activity GO:0004222 9.43 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
7 serine-type endopeptidase activity GO:0004252 9.23 IGKC IGKV1-5 MMP1 MMP12 MMP14 MMP2
Sources

Sources for Light Chain Deposition Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....